DK2809681T3 - ANTI-ASIC1-antistoffer og anvendelser deraf - Google Patents
ANTI-ASIC1-antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK2809681T3 DK2809681T3 DK13702876.7T DK13702876T DK2809681T3 DK 2809681 T3 DK2809681 T3 DK 2809681T3 DK 13702876 T DK13702876 T DK 13702876T DK 2809681 T3 DK2809681 T3 DK 2809681T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gly
- thr
- tyr
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
1. Isoleret antistof eller antigen-bindingsfragment deraf, der specifikt binder celleoverflade-udtrykt ASIC1 (SEQ ID NO: 401), hvor antistoffet eller antigenbindingsfragmentet omfatter et tungkæde-komplementaritetsbestemmende område (HCDR) 1 med aminosyresekvensen ifølge SEQ ID NO: 36, et HCDR2 med aminosyresekvensen ifølge SEQ ID NO: 38, et HCDR3 med aminosyresekvensen ifølge SEQ ID NO: 40, et letkæde-komplementaritetsbestemmende område (LCDR) 1 med aminosyresekvensen ifølge SEQ ID NO: 44, et LCDR2 med aminosyresekvensen ifølge SEQ ID NO: 46 og et LCDR3 med aminosyresekvensen ifølge SEQ ID NO: 48.
2. Isoleret antistof eller antigen-bindingsfragment ifølge krav 1, hvor antistoffet eller antigen-bindingsfragmentet omfatter et variabelt tungkædeområde (HCVR) med aminosyresekvensen ifølge SEQ ID NO: 34 og et variabelt letkædeområde (LCVR) med aminosyresekvensen ifølge SEQ ID NO: 42.
3. Isoleret antistof eller antigen-bindingsfragment deraf, der konkurrerer om binding til celleoverflade-udtrykt ASIC1 med et referenceantistof, der omfatter et HCVR med aminosyresekvensen ifølge SEQ ID NO: 34 og et LCVR med aminosyresekvensen ifølge SEQ ID NO: 42.
4. Isoleret antistof, eller antigen-bindingsfragment deraf, der specifikt binder celleoverflade-udtrykt ASIC1 (SEQ ID NO: 401), hvor antistoffet eller antigenbindingsfragmentet omfatter tung- og letkæde-CDR’er af et HCVR/LCVR-aminosyresekvenspar med aminosyresekvensen ifølge SEQ ID NO: 34 og 42.
5. Farmaceutisk sammensætning, der omfatter antistoffet eller antigenbindingsfragmentet ifølge et hvilket som helst af kravene 1 til 4 og en farmaceutisk acceptabel bærer eller fortynder.
6. Isoleret antistof eller antigen-bindingsfragment ifølge et hvilket som helst af kravene 1 til 4, eller den farmaceutiske sammensætning ifølge krav 5, til anvendelse i en fremgangsmåde til behandling eller lindring af smerte.
7. Isoleret antistof eller antigen-bindingsfragment eller farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor smerten er (a) cancer-associeret smerte eller kemoterapi-induceret smerte eller (b) nociceptiv smerte eller visceral smerte, eventuelt forbundet med en tilstand valgt fra gruppen bestående af inflammation, postoperativ incision, neuropati, knoglefraktur, forbrænding, osteoporotisk fraktur, knoglecancer, gigt, migrænehovedpine og fibromyalgi.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592837P | 2012-01-31 | 2012-01-31 | |
| US201261644038P | 2012-05-08 | 2012-05-08 | |
| US201261692925P | 2012-08-24 | 2012-08-24 | |
| PCT/US2013/023784 WO2013116296A1 (en) | 2012-01-31 | 2013-01-30 | Anti-asic1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2809681T3 true DK2809681T3 (da) | 2019-03-11 |
Family
ID=47666522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18201823.4T DK3453723T3 (da) | 2012-01-31 | 2013-01-30 | Anti-ASIC1-antistoffer og anvendelser deraf |
| DK13702876.7T DK2809681T3 (da) | 2012-01-31 | 2013-01-30 | ANTI-ASIC1-antistoffer og anvendelser deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18201823.4T DK3453723T3 (da) | 2012-01-31 | 2013-01-30 | Anti-ASIC1-antistoffer og anvendelser deraf |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US9150648B2 (da) |
| EP (2) | EP2809681B1 (da) |
| JP (1) | JP6302844B2 (da) |
| KR (1) | KR102111941B1 (da) |
| CN (1) | CN104093738B (da) |
| AR (1) | AR089852A1 (da) |
| AU (1) | AU2013215254B2 (da) |
| CA (1) | CA2862332C (da) |
| CL (1) | CL2014002019A1 (da) |
| CO (1) | CO7020877A2 (da) |
| CY (2) | CY1121368T1 (da) |
| DK (2) | DK3453723T3 (da) |
| EA (1) | EA028647B1 (da) |
| ES (2) | ES2886123T3 (da) |
| HR (2) | HRP20190358T1 (da) |
| HU (2) | HUE056335T2 (da) |
| IL (2) | IL233410A0 (da) |
| IN (1) | IN2014CN04645A (da) |
| JO (1) | JO3547B1 (da) |
| LT (2) | LT2809681T (da) |
| MX (1) | MX358518B (da) |
| MY (1) | MY168748A (da) |
| NZ (1) | NZ626242A (da) |
| PH (1) | PH12014501613B1 (da) |
| PL (2) | PL2809681T3 (da) |
| PT (2) | PT3453723T (da) |
| RS (2) | RS58439B1 (da) |
| SG (1) | SG11201403222UA (da) |
| SI (2) | SI3453723T1 (da) |
| SM (1) | SMT202100628T1 (da) |
| TW (1) | TWI591073B (da) |
| UY (1) | UY34603A (da) |
| WO (1) | WO2013116296A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ626242A (en) | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
| JP2017513854A (ja) | 2014-04-15 | 2017-06-01 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｗｉｓｐ１に結合する抗原結合タンパク質 |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| CN105233286B (zh) * | 2015-09-10 | 2018-10-30 | 上海交通大学医学院 | 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途 |
| CN105713089B (zh) * | 2016-02-26 | 2019-08-06 | 上海科技大学 | 一种特异性抑制酸敏感离子通道i型的全人抗体 |
| WO2018085441A1 (en) * | 2016-11-01 | 2018-05-11 | Berg Llc | Filamin b binding proteins and uses thereof |
| CN111936517B (zh) * | 2018-01-26 | 2025-04-18 | 瑞泽恩制药公司 | 抗tmprss2抗体和抗原结合片段 |
| AU2019449475A1 (en) * | 2019-06-04 | 2022-01-06 | Shanghaitech University | Affinity-maturated anti-ASIC1a antibodies |
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| WO2021012176A1 (en) * | 2019-07-23 | 2021-01-28 | Shanghaitech University | Asic1 channel antagonist antibody |
| AU2020346886A1 (en) * | 2019-09-13 | 2022-04-14 | Memorial Hospital For Cancer And Allied Diseases | Anti-CD371 antibodies and uses thereof |
| CN118103070A (zh) * | 2021-08-09 | 2024-05-28 | 默克专利有限公司 | 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质 |
| JP2024534892A (ja) * | 2021-09-02 | 2024-09-26 | メモリアル スローン ケタリング キャンサー センター | 抗ｄｌｌ３抗体及びその使用 |
| JP2024083709A (ja) * | 2022-12-12 | 2024-06-24 | ａｒｔｉｅｎｃｅ株式会社 | コート剤、シートおよび成形体 |
| CN119331085B (zh) * | 2024-10-16 | 2025-03-14 | 中国科学院合肥物质科学研究院 | 沙贝冠状病毒广谱中和抗体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2759373B1 (fr) | 1997-02-11 | 2001-05-04 | Centre Nat Rech Scient | Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications |
| ATE347596T1 (de) | 1997-10-29 | 2006-12-15 | Univ Mcgill | Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen |
| US6287859B1 (en) | 1998-08-05 | 2001-09-11 | Centre National De La Recherche | Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel |
| CA2304494A1 (en) | 2000-04-20 | 2001-10-20 | Philippe Seguela | A novel heteromultimeric ion channel receptor and uses thereof |
| US6635432B1 (en) | 2000-04-25 | 2003-10-21 | University Of Iowa Research Foundation | Peptide potentiation of acid-sensory ion channel in pain |
| US7132505B1 (en) | 2001-05-10 | 2006-11-07 | Centre National De La Recherche Scientifique - Cnrs | Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker |
| CA2352702A1 (en) * | 2001-07-18 | 2003-01-18 | Philippe Seguela | Novel human proton gated ion channel |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20030186860A1 (en) | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
| US20070197583A1 (en) | 2002-03-29 | 2007-08-23 | Welsh Michael J | Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction |
| PT1527100E (pt) * | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
| WO2005025518A2 (en) * | 2003-09-11 | 2005-03-24 | The Uab Research Foundation | Inhibition of inward sodium currents in cancer |
| US20070281986A1 (en) | 2004-02-03 | 2007-12-06 | Collier Gregory R | Methods and Compositions for Modulating Satiety |
| JP2007530664A (ja) | 2004-03-30 | 2007-11-01 | ペインセプター ファーマ コーポレーション | ゲートイオンチャンネルを調節するための組成物及び方法 |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7192500B2 (en) | 2004-04-30 | 2007-03-20 | Kimberly-Clark Worldwide, Inc. | Process for making a garment including an absorbent assembly |
| US8030442B2 (en) | 2004-09-16 | 2011-10-04 | Morehouse School Of Medicine | Treatment of injury to the brain by inhibition of acid sensing ion channels |
| ZA200705695B (en) * | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| CA2763671A1 (en) * | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| JP5307708B2 (ja) * | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| JP5382692B2 (ja) * | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
| WO2008007131A2 (en) * | 2006-07-14 | 2008-01-17 | Medical Research Council | Treatment for demyelinating disease |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US7598039B2 (en) | 2007-01-30 | 2009-10-06 | Academia Sinica | Treatment of insulin resistance |
| DE602008002913D1 (de) | 2007-04-03 | 2010-11-18 | Ilegusavnid Genetics Resource | Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle |
| EP2150564A2 (en) * | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| US20110262395A1 (en) * | 2008-05-08 | 2011-10-27 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
| US20090291150A1 (en) | 2008-05-21 | 2009-11-26 | University Of Iowa Research Foundation | Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity |
| FR2932091B1 (fr) | 2008-06-06 | 2012-12-28 | Centre Nat Rech Scient | Effets analgesiques de la toxine peptidique apetx2 |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| GB0922434D0 (en) * | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| CN102234316B (zh) * | 2010-05-07 | 2014-01-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有增强酸感受离子通道1a电流作用的多肽及其用途 |
| NZ626242A (en) | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
-
2013
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 SM SM20210628T patent/SMT202100628T1/it unknown
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/da active
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en not_active Ceased
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active Active
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
-
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613B1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
-
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
-
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
-
2019
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
-
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7500812B2 (ja) | 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体 | |
| DK2809681T3 (da) | ANTI-ASIC1-antistoffer og anvendelser deraf | |
| KR101781786B1 (ko) | 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체 | |
| AU2013280610B2 (en) | Anti-EGFR antibodies and uses thereof | |
| DK2475684T3 (da) | Humane højaffnititetsantistoffer mod human protease-aktiveret receptor-2 | |
| ES2694153T3 (es) | Anticuerpos anti-ErbB3 y usos de los mismos | |
| KR20140014067A (ko) | 항-cd48 항체 및 그의 용도 | |
| KR102563568B1 (ko) | 렙틴 수용체에 길항하는 항원-결합 단백질 | |
| US9371383B2 (en) | Anti-ASIC1 antibodies and uses thereof | |
| US20180208656A1 (en) | Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof | |
| HK40006818B (en) | Anti-asic1 antibodies and uses thereof | |
| HK40006818A (en) | Anti-asic1 antibodies and uses thereof | |
| HK1199269B (en) | Anti-asic1 antibodies and uses thereof |